4-(benzyloxy)-3,5-dibromobenzaldehyde | 249515-06-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(benzyloxy)-3,5-dibromobenzaldehyde
• 英文别名: 4-benzyloxy-3,5-dibromobenzaldehyde；4-benzyloxy-3,5-dibromo-benzaldehyde；4-Benzyloxy-3,5-dibrom-benzaldehyd；3,5-dibromo-4-phenylmethoxybenzaldehyde
• CAS: 249515-06-8
• 化学式: C₁₄H₁₀Br₂O₂
• mdl: MFCD01169252
• 分子量: 370.04
• InChiKey: IMYYDKQPNKYZQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2913000090

反应信息

• 作为反应物：
  描述：

  4-(benzyloxy)-3,5-dibromobenzaldehyde 在 sodium tetrahydroborate 、 N,N-二甲基乙酰胺 、 三溴化磷 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 112.5h， 生成 1-[(3,5-dibromo-4-phenylmethoxyphenyl)methyl]-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-imino-7H-purin-8-one
  参考文献：
  名称：

  Synthesis and Structure of the Marine Ascidian 8-Oxoadenine Aplidiamine.

  摘要：

  8-氧代腺苷 (13) 用 4-苄氧基-3, 5-二溴苄基溴 (20) 烷基化，然后进行 Dimroth 重排和酸水解，得到 N-(3, 5-二溴-4-羟基苄基)-8-氧代腺苷 ( 15）。该反应序列的 2'-脱氧版本首次合成了 N-(3, 5-二溴-4-羟基苄基)-8-氧化腺嘌呤 (16)，这是海洋海鞘嘌呤 aplidiamine 的正确表达。

  DOI：

  10.1248/cpb.47.1297
• 作为产物：
  描述：

  3,4-二氢苯并[cd]吲哚-5(1H)-酮 生成 4-(benzyloxy)-3,5-dibromobenzaldehyde
  参考文献：
  名称：

  BUCHAN G. M.; TURNER A. B., J. CHEM. SOC. PERKIN TRANS. PART 1 , 1975, NO 22, 2257-2261

  摘要：

  DOI：

文献信息

• [EN] AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF<br/>[FR] AGONISTES ET ANTAGONISTES DU RÉCEPTEUR S1P5, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBOTT LAB

  公开号：WO2010093704A1

  公开（公告）日：2010-08-19

  Disclosed are compounds that are agonists or antagonists of the S1P5 receptor, compositions comprising said compounds, and methods of using said compounds and compositions. In certain embodiments, said compounds are 1-benzylazetidine-3-carboxylic acid derivatives. In certain embodiments, said methods relate to the treatment of neuropatic pain and/or a neurodegenerative disorder. In certain embodiments, said compounds may be used in combination with a second therapeutic agent.

  本文披露了作为S1P5受体激动剂或拮抗剂的化合物，包括含有这些化合物的组合物，以及使用这些化合物和组合物的方法。在某些实施例中，这些化合物是1-苄基氮杂环丙氨酸衍生物。在某些实施例中，这些方法涉及治疗神经痛和/或神经退行性疾病。在某些实施例中，这些化合物可以与第二治疗剂结合使用。
• [EN] 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE<br/>[FR] 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES ET PROCÉDÉS D'UTILISATION
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2018183587A1

  公开（公告）日：2018-10-04

  The present invention generally relates to 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles as a ubiquitin specific protease 7 (USP7) inhibitor useful for the treatment of diseases mediated by malfunction of USP7, such as inflammation, cancer, and immunological disorders. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases mediated by malfunction of USP7, in mammals using compounds disclosed herein.

  本发明通常涉及6-氨基-2,4-二氢吡喃并[2,3-c]吡唑醇作为一种泛素特异性蛋白酶7（USP7）抑制剂，用于治疗由USP7功能失调介导的疾病，如炎症、癌症和免疫性疾病。本文所述的发明还涉及使用本文披露的化合物在哺乳动物中治疗由USP7功能失调介导的疾病的药物组合物和方法。
• [EN] 1- 2' (1, 4'-BIPERIDIN-1'-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS<br/>[FR] DERIVES DE 1- 2' (1, 4'-BIPERIDIN-1'-YL)-1- (PHENYL) ETHYL CYCLOHEXANOL UTILES COMME MODULATEURS DU RECAPTAGE DE MONOAMINE DANS LE TRAITEMENT DES SYMPTOMES VASOMOTEURS
  申请人：WYETH CORP

  公开号：WO2005037279A1

  公开（公告）日：2005-04-28

  The present invention is directed to substituted N-heterocycle derivatives of formula (I), compositions containing these derivatives, and their use in the manufacture of a medicament for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof wherein : A is phenyl, naphthyl, thiophenyl, pyridinyl, furanyl, benzofuranyl, isobenzofuranyl, xanthenyl, pyrrolyl, indolizinyl, isoindolyl, indolyl, or benzothiophenyl, where 1 to 3 carbon atoms of said A is optionally replaced with a nitrogen atom; U is N or O; W is H or OR8; the other substituents are defined in the claims.

  本发明涉及式（I）的取代N-杂环衍生物，含有这些衍生物的组合物，以及它们在制造用于预防和治疗由单胺再摄取改善的病况的药物中的应用，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病以及其中的组合，特别是从主要抑郁障碍、血管运动症状、压力和急迫性尿失禁、纤维肌痛、疼痛、糖尿病性神经病变以及其中的组合中选择的那些病况，其中：A是苯基、萘基、噻吩基、吡啶基、呋喃基、苯并呋喃基、异苯并呋喃基、黄色素基、吡咯基、吲哚啉基、异吲哚基、吲哚基或苯并噻吩基，其中所述A的1至3个碳原子可选择地被氮原子取代；U是N或O；W是H或OR8；其他取代基在权利要求中定义。
• [EN] SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE<br/>[FR] DERIVES DE CYCLOALCANOYL ARYLE SUBSTITUES ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：WYETH CORP

  公开号：WO2005037809A1

  公开（公告）日：2005-04-28

  The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及取代芳基环烷酰衍生物，含有这些衍生物的组合物，以及它们用于预防和治疗由单胺再摄取改善的病况的方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病，以及这些疾病的组合，尤其是从包括重性抑郁障碍、血管运动症状、压力和急迫性尿失禁、纤维肌痛、疼痛、糖尿病神经病变等病况中选出的那些病况。
• [EN] ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE<br/>[FR] DERIVES D'ARYLALKYL-PIPERAZINE ET DE CYCLOALKYLALKYL-PIPERAZINE ET METHODES D'UTILISATION ASSOCIEES
  申请人：WYETH CORP

  公开号：WO2005037807A1

  公开（公告）日：2005-04-28

  The present invention is directed to arylalkyl- and cycloalkylalkyl-piperazine derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及芳基烷基和环烷基哌嗪衍生物，含有这些衍生物的组合物，以及它们用于预防和治疗由单胺再摄取改善的病况的方法，包括但不限于血管运动症状（VMS），性功能障碍，胃肠和泌尿系统疾病，慢性疲劳综合征，纤维肌痛综合征，神经系统疾病等，特别是那些选自主要抑郁症、血管运动症状、压力性和切望性尿失禁、纤维肌痛综合征、疼痛、糖尿病性神经病变等病况的组合物。